

21 Dec 2016 |

# Top M&A Of 2016: Cast Your Vote!

by Nancy Dvorin

It's time once again for **In Vivo's Deal of the Year** contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to [pick the winners](#). (It's free.)

## In Vivo's Top M&A Of 2016 – The Nominees Are

A Big Year For NASH: Allergan PLC built anon-alcoholic steatohepatitis franchise overnight in mid-September, acquiring [Tobira Therapeutics Inc.](#) for \$1.7bn and [Akarna Therapeutics Inc.](#) for \$50m. In April, [Gilead Sciences Inc.](#) paid \$400m up front plus earn-outs for its fourth NASH project, [Nimbus Apollo Inc.](#) and its Phase II-ready ACC inhibitor for NASH. (Also see "[Allergan's Tab For Tobira's NASH Cocktail With Akarna Chaser Tops \\$1.7bn](#)" - Scrip, 21 Sep, 2016.) (Also see "[Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease](#)" - Scrip, 5 Apr, 2016.) [[See Deal](#)][[See Deal](#)]

LabCorp Strengthens Women's Health Offering With Sequenom Buy: In July, LabCorp of America announced its intent to acquire noninvasive prenatal testing specialist [Sequenom Inc.](#) in an all-cash deal. The transaction enables LabCorp to broaden its test offerings in women's health and expand its geographic reach, among other things. (Also see "[LabCorp Broadens Women's Health Offering With Sequenom Buy](#)" - Medtech Insight, 27 Jul, 2016.) [[See Deal](#)]

Pfizer Prevails In Medivation Bidding War: In the biggest pharma M&A deal of the year to date, [Pfizer Inc.](#) bested multiple competitors with a \$14bn in August bid for prostate cancer drug developer [Medivation Inc.](#), showing just how far big pharma's are willing to go to compete in oncology. (Also see "[Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?](#)" - Scrip, 23 Aug, 2016.) [[See Deal](#)]

Abbott Buys St. Jude For \$25bn: This April deal was the biggest medtech acquisition of the year, and created huge consolidation in the cardiovascular device market. (Also see "[Third Cardiovascular Giant Coming With \\$25 Bil. Abbott-St. Jude Deal](#)" - Medtech Insight, 28 Apr, 2016.) [[See Deal](#)]

QuintilesIMS: Big Merger In Big Data: CRO [\*Quintiles Transnational Holdings Inc.\*](#) merged with health care data giant [\*IMS Health Inc.\*](#) in May in a deal worth \$9bn. QuintilesIMS will have a market cap close to \$18bn, not to mention a huge head start in finding real-world evidence solutions for clients. (Also see "[\*QuintilesIMS' Chan On Real-World Evidence Hubs, Reverse Innovation\*](#)" - Scrip, 11 Dec, 2016.)

---

[\*\*\*CLICK HERE To Cast Your Vote For The Most Significant M&A Of 2016\*\*\*](#)

[\*\*\*CLICK HERE To Cast Your Vote For The Most Significant Financing Of 2016\*\*\*](#)

[\*\*\*CLICK HERE to Cast Your Vote For The Most Significant Strategic Alliance Of 2016\*\*\*](#)

---